Organon And Henlius Complete Phase III For Denosumab
Pair’s HLX14 Partnered Biosimilar Rival To Prolia/Xgeva Meets Primary Endpoints
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
